Case Report: Elevated myocardial enzymes in a patient with metastatic rectal cancer without myocardial injury. (PubMed, Front Oncol)
A 67-year-old male patient with advanced rectal cancer and multiple metastases received chemotherapy with oxaliplatin and capecitabine, targeted therapy with bevacizumab, denosumab for bone metastases, and local radiotherapy. However, when the condition deteriorated and the number of metastatic lesions increased, the expression levels of myocardial enzymes sharply rose again, eventually accompanying the patient's death. The non-cardiac injury-related increase in myocardial enzymes is closely associated with tumor burden and cancer activity, and can serve as a dynamic indicator for evaluating the efficacy of radiotherapy and chemotherapy and disease progression.